TCT 2017 | INTREPID: Mitral Replacement with a Self-Expanding Device

Courtesy of the SBHCI.

Intrepid is a 43-, 46-, and 50-mm nitinol self-expanding valve with bovine pericardial leaflets that is placed using a transapical delivery system with a 35-Fr access.

This pilot study enrolled 50 patients with severe mitral regurgitation who were symptomatic and at a high surgical risk, or in whom surgery was contraindicated.

Read also: “TCT 2017 | MAVERIC: Results 6 Months After Transcatheter Mitral Valve Replacement”.

The rate of implantation success was 98%; the rate of 30-day mortality was 14% and 1-year survival was 77%. In patients who survived 1 year, there was no device dysfunction, hemolysis, thrombosis, or residual mitral regurgitation. After a 1-year follow-up, 79% of all survivors presented a New York Heart Association (NYHA) functional class I-II.

Conclusion

Treatment with the Intrepid device was feasible and able to correct mitral regurgitation in patients at high or extreme surgical risk.

Courtesy of the SBHCI.

Original title: 30-Day Outcomes of Transcatheter MV Replacement in Patients With Severe Mitral Regurgitation.

Presenter: Paul Sorajja.

INTREPID

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.